Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-CLS-616 Phase 1 First-in-Human Study in Healthy Volunteers
NCT06698926Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABBV-CLS-616 (14 arms), sponsored by AbbVie Inc. Primary endpoint: Adverse Events at 90 days. Started Nov 2024; status: completed.
02
Drugs
ABBV-CLS-616
Beyond the preview
Go deeper on NCT06698926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06698926.